2025-06-13-Jefferies-邀请_ALKS_JAZZ_TAK关于食欲素的关键意见领袖电话会议-美国东部时间今日上午9点_31页_2mb

Equity Research Summary: ALKS/JAZZ/TAK Orexin Space KOL Call

A KOL call event involving Dr. Thomas E. Scammell, MD (Professor of Neurology, Harvard Medical School) is scheduled for June 13, 2025, at 9 AM ET to discuss the neurobiology of Orexins, clinical development of orexin agonists (ALKS-2680, TAK-861, TAK-994), and market opportunities in Narcolepsy and Idiopathic Hypersomnia (IH).

Key Topics Discussed:

1. OREXIN Biology & Pathophysiology:

• Function: Orexin-A & B (Hypocretin-1/2) regulate sleep-wake states, with low levels linked to Narcolepsy Type 1 (NT1), Diurnal Hypocretin fluctuations in NT2 vs Normal.
• ** OX Receptors**: OX1R binds orexin-A preferentially, while OX2R is pan-selective; GPCR signaling affects neuronal excitability and tachyphylaxis risk.

2. Drug Candidates & Clinical Data:

• ALKS-2680: Selective OX2R agonist; Phase 1b trials show dose-dependent wakefulness effects in NT1, NT2, IH; Adding Electroencephalogram-derived sleep score (ESS) as a primary endpoint in NT2 trial.
• TAK-861 & TAK-994: Lead OX2 agonists; Preclinical data shows sustained clinical benefit with repeated dosing, though β-arrestin recruitment and receptor desensitization pose challenges for efficacy over time.
• Tachyphylaxis: Key concern with GPCR agonists—risk of efficacy reduction at higher doses or with prolonged use, potentially related to β-arrestin signaling and receptor recycling.

3. Efficacy & Clinical Endpoints:

• Primary endpoints: Maintenance Wake Time (MWT), Epworth Sleepiness Scale (ESS), Quality EEG (qEEG) correlates (beta power).
• Research suggests flat PK tails may contribute to insomnia concerns at night; need for optimal receptor–β-arrestin balance.

4. Safety & Adverse Effects:

• AEs include Urinary Urgency, Insomnia, Visual Disturbances. Primarily linked to central OX2R activation, potentially mitigated with lower doses. Risk of liver toxicity debated with metabolite balance.

5. Market Opportunity:

• Narcolepsy market ($>2.5Bn), ≈30% NT1:70% NT2 prevalence. Orexin agonists could address unmet needs; potential label expansion to ADHD, Major Depressive Disorder (MDD), Multiple Sclerosis fatigue, etc. shows preclinical promise for broad applications.

Conclusion Insights:
The orexin space offers a significant opportunity for Narcolepsy and IH treatments. Tachyphylaxis risk requires careful management, primarily through understanding GPCR pharmacology. ALKS-2680 showed initial positive results, but further Phase 2 trials (H2 2025) needed for efficacy data at multiple dosing; TAK agonists remain competitive. Continued exploration into off-Narcolepsy applications (ADHD, MDD) could expand revenue potential.